Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.
Immune cell
Immunotherapy
Localized
Renal cell carcinoma
Tumor infiltrating lymphocytes
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
28 05 2019
28 05 2019
Historique:
received:
07
02
2019
accepted:
16
05
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
25
7
2020
Statut:
epublish
Résumé
The tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the correlation of tumor infiltrating immune cell characteristics with rates of recurrence following surgery in localized ccRCC. We morphologically identified and scored tumor infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) stained slides of patients with localized ccRCC (stage ≥T1b excluding stage IV). The University of Alabama at Birmingham (UAB) dataset (n = 159) was used to discover and the Fox Chase Cancer Center (FCCC) dataset (n = 198) was used to validate the results of morphologic immune cell analysis. We then performed gene expression analysis using the Immune Profile panel by NanoString in the UAB cohort and identified immune cells and pathways associated with recurrence, followed by validation in the Cancer Genome Atlas (TCGA) ccRCC dataset. Infiltrating immune cell types were identified by gene expression deconvolution. The presence of TILs identified by morphology correlated with higher T cell, Th1, CD8+ T and Treg gene signatures. Recurrence was associated with lower T cells and higher neutrophils. Higher Teffector (Teff)/Treg ratio correlated with lower rate of recurrence and was validated in the TCGA dataset. Genes associated with adaptive immune response were downregulated in tumors that recurred. Unsupervised hierarchical clustering identified a subset of patients with over-expression of adaptive response genes including CD8, CD3, GZMA/B, PRF1, IDO1, CTLA4, PDL1, ICOS and TIGIT. These patients had higher morphologic lymphocyte infiltration and T cell gene expression. Higher levels of TILs identified by morphology correlated with higher rates of recurrence in our discovery dataset but not in our validation set. Recurrence of ccRCC following surgery was associated with lower T cell infiltrate, lower adaptive immune response and higher neutrophil gene expression. Presence of higher Teff/Treg ratio correlated with lower recurrence.
Sections du résumé
BACKGROUND
The tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the correlation of tumor infiltrating immune cell characteristics with rates of recurrence following surgery in localized ccRCC.
METHODS
We morphologically identified and scored tumor infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) stained slides of patients with localized ccRCC (stage ≥T1b excluding stage IV). The University of Alabama at Birmingham (UAB) dataset (n = 159) was used to discover and the Fox Chase Cancer Center (FCCC) dataset (n = 198) was used to validate the results of morphologic immune cell analysis. We then performed gene expression analysis using the Immune Profile panel by NanoString in the UAB cohort and identified immune cells and pathways associated with recurrence, followed by validation in the Cancer Genome Atlas (TCGA) ccRCC dataset. Infiltrating immune cell types were identified by gene expression deconvolution.
RESULTS
The presence of TILs identified by morphology correlated with higher T cell, Th1, CD8+ T and Treg gene signatures. Recurrence was associated with lower T cells and higher neutrophils. Higher Teffector (Teff)/Treg ratio correlated with lower rate of recurrence and was validated in the TCGA dataset. Genes associated with adaptive immune response were downregulated in tumors that recurred. Unsupervised hierarchical clustering identified a subset of patients with over-expression of adaptive response genes including CD8, CD3, GZMA/B, PRF1, IDO1, CTLA4, PDL1, ICOS and TIGIT. These patients had higher morphologic lymphocyte infiltration and T cell gene expression. Higher levels of TILs identified by morphology correlated with higher rates of recurrence in our discovery dataset but not in our validation set.
CONCLUSIONS
Recurrence of ccRCC following surgery was associated with lower T cell infiltrate, lower adaptive immune response and higher neutrophil gene expression. Presence of higher Teff/Treg ratio correlated with lower recurrence.
Identifiants
pubmed: 31138299
doi: 10.1186/s40425-019-0621-1
pii: 10.1186/s40425-019-0621-1
pmc: PMC6540413
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA013148
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232097
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Br J Cancer. 2003 Nov 17;89(10):1906-8
pubmed: 14612901
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Clin Pathol. 2012 Feb;65(2):159-63
pubmed: 22049225
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Hum Immunol. 2014 Jul;75(7):614-20
pubmed: 24801648
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Clin Cancer Res. 2015 Mar 1;21(5):1071-7
pubmed: 25538263
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Genome Biol. 2014 Dec 20;15(12):563
pubmed: 25608759
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
N Engl J Med. 2017 Mar 2;376(9):893
pubmed: 28249133
JAMA Oncol. 2017 Sep 1;3(9):1249-1252
pubmed: 28278333
J Clin Oncol. 2017 Dec 10;35(35):3916-3923
pubmed: 28902533
Clin Cancer Res. 2018 Apr 1;24(7):1554-1561
pubmed: 29374054
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Natl Cancer Inst. 2019 Jan 1;111(1):69-77
pubmed: 29788230
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Clin Cancer Res. 2019 Mar 1;25(5):1526-1534
pubmed: 30201760
Front Oncol. 2018 Sep 25;8:390
pubmed: 30319963
Ann Oncol. 2018 Dec 1;29(12):2371-2378
pubmed: 30346481